Dr. Lonial on Advancements in the Treatment of Myeloma

Sagar Lonial, MD, FACP
Published: Thursday, Mar 02, 2017



Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer at Winship Cancer Institute of Emory University, discusses recent advancements in the field of multiple myeloma.

In myeloma, the paradigm has completely changed from 10 to 15 years ago, Lonial explains. The drugs were relatively ineffective in the induction setting and were dependent on high-dose therapy and autologous transplant to do much of the work when trying to induce remissions.

Now, what the field has are very highly active induction regimens that allow us to put the majority of patients in remission for between 3 and 5 years in just the first round of therapy, Lonial states.
 
SELECTED
LANGUAGE


Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer at Winship Cancer Institute of Emory University, discusses recent advancements in the field of multiple myeloma.

In myeloma, the paradigm has completely changed from 10 to 15 years ago, Lonial explains. The drugs were relatively ineffective in the induction setting and were dependent on high-dose therapy and autologous transplant to do much of the work when trying to induce remissions.

Now, what the field has are very highly active induction regimens that allow us to put the majority of patients in remission for between 3 and 5 years in just the first round of therapy, Lonial states.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x